The British researchers have found that a breast cancer wonder drug could be turned into universal weapon against global weapon against tumours. The team from the Newcastle University has identified a technique of making a family of breast cancer pills effective against other cancers.
The new finding could escort to new drugs which shrivel several or all types of tumours. The cancer drugs known as PARP inhibitors target the way cancer cells repair themselves. The drugs target hereditary forms of breast cancer, ovarian prostate cancer and pancreatic tumours with the similar rogue gene.
The drugs exploit the Achilles heel which is hereditary forms of breast cancer. This is caused by a flaw in a gene called BRCA1, which limits the ability of cells to repair damage to their DNA. Healthy cells have two ways of darning damage that allows them to breed, grow and spread.
These drugs are of particular interest to doctors as they zilch in on the tumour, and exterminate it without harming healthy cells. The patients suffer less side effects than chemotherapy or radiotherapy, in which healthy cells are affected. The PARP inhibitors wedge the remaining alleyway, hating the tumour cells from proliferating and ultimately escorting to death.
In the lab trail on mice with lung cancer, researchers revealed that jamming a molecule called Cdk1 also halted DNA repair. When rodents were give PARP inhibitors, it effectively shriveled their tumours. According to lead researcher Prof Nicola Curtin, blocking Cdk1 negotiates DNA repair in cancer cells, making them sensitive to PARP inhibitors. The study published in journal Nature Medicine.
Now they need to develop an effective drug that can block Cdk1, so more patients can benefit from treatment with PARP inhibitors. It could be extensively relevant, perhaps universally. The very fact that the defect that makes cells susceptible to PARP inhibitors can be recreated in lung cancer is pretty hopeful, added Dr Curtin. The study published in the journal Nature Medicine.